BridgeBio Muscular Dystrophy Therapy Receives FDA Priority Review

BridgeBio's therapy for muscular dystrophy has been granted priority review by the FDA, potentially accelerating its path to market. This move indicates the FDA's recognition of the drug's potential to address an unmet medical need.